{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001017731,0.0005088613,0.000930234,0.0002403494,0.0001847662,0.0005018871,0.0003225921,0.000441163,0.001985405],"category_scores_gemma":[0.0006497307,0.0003089764,0.0008249753,0.0002490696,0.0002756896,0.0003352673,0.0002259801,0.001113414,0.0003939196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004716797,"about_ca_system_score_gemma":0.0005680472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006287582,"about_ca_topic_score_gemma":0.002133267,"domain_scores_codex":[0.999685,0.0001828504,0.00001569677,0.00003700365,0.00003411841,0.00004532568],"domain_scores_gemma":[0.9997094,0.0000655184,0.00006897622,0.00002118095,0.00002009719,0.0001147271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7574698,0.01671321,0.02129646,0.0009462241,0.003184005,0.000177556,0.0001664725,0.002097182,0.03708604,0.0001447688,0.002903668,0.1578147],"study_design_scores_gemma":[0.4336295,0.4730378,0.07618814,0.0000819798,0.002513566,0.0003060519,0.00007179294,0.00229794,0.007187608,0.0001756916,0.004478048,0.0000318862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965566,0.001806687,0.0001441797,0.0001861067,0.00004357412,0.0003340086,0.0002441846,0.00002592486,0.0006587188],"genre_scores_gemma":[0.9967138,0.0009977483,0.0004077006,0.0001874823,0.0000687854,0.0002915883,0.0004967999,0.000005926735,0.00083023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001985405,"threshold_uncertainty_score":0.006641805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008657859952414042,"score_gpt":0.2774406519264998,"score_spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}